DEPARTMENT OF THE AIR FORCE
HEADQUARTERS UNITED STATES AIR FORCE
WASHINGTON DC

27 April 2010

MEMORANDUM FOR ALMAJCOM/SG

FROM: HQ USAF/SG3
1500 Wilson Boulevard, Suite 1200
Arlington, VA 22209

SUBJECT: Assistant Secretary of Defense for Health Affairs Memo, "Suspension of Anthrax Vaccine Adsorbed Registry Reporting Requirements"

This memorandum supports the attached memorandum from the Assistant Secretary of Defense for Health Affairs suspending the requirement for monthly anthrax vaccine adsorbed (AVA) reports and vaccination site registration. Since the Emergency Use Authorization originally granted by the Food and Drug Administration (FDA) in 2005 is no longer in effect, these reports and the registration of vaccination sites are no longer needed by the Department of Defense leadership or the FDA. The March 2010 monthly report, (due on 5 April 10), will be the final AVA report to MILVAX. AVA registry agreements are no longer required effective 13 April 2010.

It is important to remember that the 18 Jan 07 Anthrax Vaccine Implementation Plan and medical logistics monthly reporting requirements concerning vaccine supplies on-hand have not been rescinded and remain in effect. Please ensure that MTFs continue their strong focus on this very important force protection program.

My POC for this memorandum is Lt Col Michael Lundy, AFMSA/SG3PM, (703) 588-6466, DSN 425-6466, or Michael.Lundy@pentagon.af.mil.

TIMOTHY T. JEX, Colonel, USAF, MC, CFS
Deputy Assistant Surgeon General, Health Care Operations
Office of the Surgeon General

Attachments:
1. Assistant Secretary of Defense for Health Affairs Memo, 25 Mar 10
2. MILVAX Memo, 13 Apr 10

SG3 Doc 2010-044

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
WASHINGTON, DC 20301-1200

HEALTH AFFAIRS

MAR 25 2010

MEMORANDUM FOR DIRECTOR, MILITARY VACCINE AGENCY

SUBJECT: Suspension of Anthrax Vaccine Adsorbed Registry Reporting Requirements

In December 2006, the Under Secretary of Defense for Personnel and Readiness directed the Military Vaccine Agency to maintain verification and reporting requirements for Anthrax Vaccine Adsorbed at facilities administering the vaccine. This administrative requirement would continue until suspended by the Assistant Secretary of Defense for Health Affairs.

Since the Emergency Use Authorization originally granted by the Food and Drug Administration in 2005 is no longer in effect, the reports are no longer needed by the Department of Defense leadership or FDA. Therefore, the administrative reporting requirements are suspended for any new or currently registered clinical sites until further notice. Although site registration and monthly reports are suspended, Military Service Anthrax Vaccine Implementation Plans remain in effect. This suspension does not include medical logistics reporting requirements concerning on-hand vaccine. Anthrax vaccine remains a critically important part of the Force Health Protection and Readiness Program of the Armed Forces.

Charles L. Rice, M.D.
President, Uniformed Services University of the Health Sciences
Performing the Duties of the
Assistant Secretary of Defense
(Health Affairs)

DEPARTMENT OF THE ARMY
OFFICE OF THE SURGEON GENERAL
5113 LEESBURG PIKE
FALLS CHURCH VA 22041

REPLY TO
ATTENTION OF

DASG-HCA

13 April 2010

MEMORANDUM FOR MILVAX Service Liaisons

SUBJECT: Suspension of Registration and Monthly Reporting for the Anthrax Vaccine Immunization Program (AVIP)

1. References:

a. Under Secretary of Defense (Personnel & Readiness), Memorandum, Subject: Implementation of the Anthrax Vaccine Immunization Program (AVIP), 6 Dec 06.

b. Assistant Secretary of Defense, Health Affairs, Memorandum, Subject: Suspension of Anthrax Vaccine Absorbed Registry Reporting Requirements, 25 Mar 10.

2. In December 2006, the Under Secretary of Defense for Personnel Readiness directed the Services and Military Vaccine Agency to continue the AVIP registration and monthly reporting requirements for all clinical sites administering the anthrax vaccine. These requirements were originally created under an Emergency Use Authorization.

3. Effective 13 April 2010, registry agreements are no longer required. The March 2010 monthly report, due 5 April 2010, will be the final close out report.

a. The Service Anthrax Vaccine Implementation Plans remain in effect, located at: http://www.anthrax.mil/resource/policies/policies.asp.

b. The anthrax and smallpox monthly inventory reports required by the US Army Medical Materiel Agency, per MMQC-07-1073\UPDATED ANTHRAX AND SMALLPOX VACCINE MONTHLY INVENTORY, remain in effect.

4. My point of contact for this memorandum is Ms. Traci Vactor, phone: (703) 681-2885 and email: traci.vactor@us.army.mil.

MICHAEL J. KRUKAR
Colonel, US Army
Director, Military Vaccine Agency